AngioDynamics (ANGO) Tops Q2 EPS by 21c; Guides Roughly In-Line

AngioDynamics (NASDAQ: ANGO) reported Q2 EPS of $0.37, $0.21 better than the analyst estimate of $0.16. Revenue for the quarter came in at $89 million versus the consensus estimate of $91.09 million.

GUIDANCE:

AngioDynamics sees FY2017 EPS of $0.65-$0.67, versus the consensus of $0.66. AngioDynamics sees FY2017 revenue of $335-360 million, versus the consensus of $361.7 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy